For the past few decades, millions of humans have succumbed to different types of cancer, making it one of the leading causes of death around the globe. The scientific community, researchers, and governments have reacted by trying to get functional treatments and therapies, but a lot still needs to be done. One of the researchers who has been on the front line in looking for a cure for the menace is Dr. Clay Siegall. He is the founder of a Seattle based clinical trials company, Seattle Genetics. The company specializes in antibody based cancer therapies and treatments.
Clay co-founded Seattle Genetics in 1998 which was after working for various companies as a researcher. He serves as the CEO and the chairman of the board of directors of the enterprise. When they started out, their research labs had inadequate facilities. It was his resilience and strong leadership that saw the company through some of their toughest times and to the success they are now enjoying. Looking back at the journey the company has been through, it is hard to believe that there was a time when Clay did not even have an idea where he would get the next month’s salaries for his employees.
Things started getting better in 2005 when the company was listed on NASDAQ. The best part came when one of their antibody based treatments was approved for use in fighting cancer two years ago. The company has made millions of dollars in sales for the single drug since its approval, and the market keeps getting better. Currently, there are more than 60 countries which have endorsed the drug.
The future is looking bright for Clay and Seattle Genetics. For instance, he has been working on 11 other drugs, and there is hope that they will also get the nod from the FDA. The company has been making some expansions in their facilities and hiring more staff to expedite the process. The journey has been exciting for Clay and his business, but they hope that they will be the ones to make a difference by treating cancer once and for all using antibody-based treatments.
The company has gained a lot of financial autonomy since they started selling their first FDA approved drug. Before that, they used to rely on donor funds to meet their operational costs. They estimate that they will manage to make more than a million dollars from sales in the next two to three years. Clay Siegall is an exemplary leader.